Table 1 CP1108 prevalence, mean progression-free survival (mPFS) results in the optimized biomarker positive groups and in TC score subgroups from visual scoring

From: Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC

Feature

Prevalence

mPFS [months]

Log-rank p-value

Visual %TC ≥ 1

87% (136/157)

2.7

p = 0.5359

Visual %TC ≥ 50

41% (64/157)

5.4

p = 0.0007

PD-L1 QCS-PMSTC > 3%

52% (82/157)

4.7

p < 0.0001

Back to article page